ANAVEX 1-41, or ANAVEX1-41, is an experimental drug which is or was under development for the treatment of depressive disorders, neurodegenerative disorders, and stroke. It is a sigma σ1 receptor agonist (Ki = 44nM), non-selective muscarinic acetylcholine receptor modulator (Ki = 18–114nM), and sodium and chloride channel modulator. The drug is a positional isomer of blarcamesine (ANAVEX 2-73) and has similar actions. It was under development by Anavex Life Sciences. ANAVEX 1-41 reached the preclinical research stage of development prior to no recent development being reported as of 2022. It was intended as a backup compound for blarcamesine. The drug was first described in the scientific literature by 2007.
See also List of investigational antidepressants Blarcamesine (ANAVEX 2-73) ANAVEX 3-71 (AF710B)
References